Literature DB >> 20195905

Validation of the PAGI-SYM and PAGI-QOL among healing and maintenance of erosive esophagitis clinical trial participants.

Kathleen W Wyrwich1, Reema Mody, Lois M Larsen, Misun Lee, Neesha Harnam, Dennis A Revicki.   

Abstract

BACKGROUND AND AIMS: Valid instruments are needed to assess important patient-reported outcomes (PROs) in erosive esophagitis (EE).
METHODS: Data from 4,092 patients in clinical trials to determine efficacy of dexlansoprazole MR to heal EE and maintain healed EE were used to assess the psychometric properties of the Patient Assessment of Upper Gastrointestinal Disorders-Quality of Life (PAGI-QOL) and the PAGI-Symptoms Severity Index (PAGI-SYM). A daily diary, gastroesophageal reflux disease (GERD) Symptoms Investigator Assessment and endoscopy results were also used in this study.
RESULTS: PAGI-QOL and PAGI-SYM subscales and total score internal consistency reliability estimates for both studies were acceptable (Cronbach's alpha coefficient = 0.81-0.97). Most subscale and total scores yielded moderate-to-strong correlations with other measures reflecting signs and symptoms of EE. Some subscales were able to detect differences >1 standard error of measurement (SEM) in change scores among patients with improved heartburn frequency compared to those with stable/worsening heartburn frequency in the healing study. Those with relapsed EE demonstrated differences >1 SEM in some PAGI-QOL and PAGI-SYM subscale or total scores compared to patients who maintained their healing status.
CONCLUSION: The findings of this study support the consideration of the PAGI-QOL and PAGI-SYM in future clinical trials and in the general EE population.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20195905     DOI: 10.1007/s11136-010-9620-x

Source DB:  PubMed          Journal:  Qual Life Res        ISSN: 0962-9343            Impact factor:   4.147


  17 in total

1.  Cross-cultural development and validation of a patient self-administered questionnaire to assess quality of life in upper gastrointestinal disorders: the PAGI-QOL.

Authors:  Christine de la Loge; Elyse Trudeau; Patrick Marquis; Peter Kahrilas; Vincenzo Stanghellini; Nicholas J Talley; Jan Tack; Dennis A Revicki; Anne M Rentz; Dominique Dubois
Journal:  Qual Life Res       Date:  2004-12       Impact factor: 4.147

2.  Prevalence and socioeconomic impact of upper gastrointestinal disorders in the United States: results of the US Upper Gastrointestinal Study.

Authors:  Michael Camilleri; Dominique Dubois; Bernard Coulie; Michael Jones; Peter J Kahrilas; Anne M Rentz; Amnon Sonnenberg; Vincenzo Stanghellini; Walter F Stewart; Jan Tack; Nicholas J Talley; William Whitehead; Dennis A Revicki
Journal:  Clin Gastroenterol Hepatol       Date:  2005-06       Impact factor: 11.382

3.  Rabeprazole improves health-related quality of life in patients with erosive gastroesophageal reflux disease.

Authors:  John F Johanson; Reshmi Siddique; Anne M Damiano; Leonard Jokubaitis; Anita Murthy; Ashoke Bhattacharjya
Journal:  Dig Dis Sci       Date:  2002-11       Impact factor: 3.199

4.  Treatment of gastroesophageal reflux disease: defining endpoints that are important to patients.

Authors:  Nimish Vakil
Journal:  Rev Gastroenterol Disord       Date:  2004

Review 5.  Symptom and health-related quality-of-life measures for use in selected gastrointestinal disease studies: a review and synthesis of the literature.

Authors:  A M Rentz; C Battista; E Trudeau; R Jones; P Robinson; S Sloan; S Mathur; L Frank; D A Revicki
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

6.  Esomeprazole versus other proton pump inhibitors in erosive esophagitis: a meta-analysis of randomized clinical trials.

Authors:  Ian M Gralnek; Gareth S Dulai; M Brian Fennerty; Brennan M R Spiegel
Journal:  Clin Gastroenterol Hepatol       Date:  2006-12       Impact factor: 11.382

7.  Effect of pantoprazole in older patients with erosive esophagitis.

Authors:  K R DeVault; D M Morgenstern; R B Lynn; D C Metz
Journal:  Dis Esophagus       Date:  2007       Impact factor: 3.429

Review 8.  A systematic review of symptomatic outcomes used in oesophagitis drug therapy trials.

Authors:  N Sharma; C Donnellan; C Preston; B Delaney; G Duckett; P Moayyedi
Journal:  Gut       Date:  2004-05       Impact factor: 23.059

9.  Psychological factors, quality of life, and gastrointestinal symptoms in patients with erosive and non-erosive reflux disorder.

Authors:  Zoltán Kovács; Olga Kerékgyártó
Journal:  Int J Psychiatry Med       Date:  2007       Impact factor: 1.210

10.  Responsiveness and interpretation of a quality of life questionnaire specific to upper gastrointestinal disorders.

Authors:  Christine De La Loge; Elyse Trudeau; Patrick Marquis; Dennis A Revicki; Anne M Rentz; Vincenzo Stanghellini; Nicholas J Talley; Peter Kahrilas; Jan Tack; Dominique Dubois
Journal:  Clin Gastroenterol Hepatol       Date:  2004-09       Impact factor: 11.382

View more
  5 in total

1.  Duodenal rather than antral motility contractile parameters correlate with symptom severity in gastroparesis patients.

Authors:  K Barshop; K Staller; J Semler; B Kuo
Journal:  Neurogastroenterol Motil       Date:  2014-12-17       Impact factor: 3.598

2.  Factors that contribute to the impairment of quality of life in gastroparesis.

Authors:  Henry P Parkman; Laura A Wilson; Katherine P Yates; Kenneth L Koch; Thomas L Abell; Richard W McCallum; Irene Sarosiek; Braden Kuo; Zubair Malik; Ron Schey; Robert J Shulman; Madhusudan Grover; Gianrico Farrugia; Laura Miriel; James Tonascia; Frank Hamilton; Pankaj J Pasricha
Journal:  Neurogastroenterol Motil       Date:  2021-01-25       Impact factor: 3.598

3.  Randomized clinical trial: effect of the 5-HT4 receptor agonist revexepride on reflux parameters in patients with persistent reflux symptoms despite PPI treatment.

Authors:  J Tack; F Zerbib; K Blondeau; S B des Varannes; H Piessevaux; J Borovicka; F Mion; M Fox; A J Bredenoord; H Louis; S Dedrie; M Hoppenbrouwers; A Meulemans; A Rykx; L Thielemans; M Ruth
Journal:  Neurogastroenterol Motil       Date:  2014-12-21       Impact factor: 3.598

4.  Development and Validation of the Chronic Gastritis Scale Under the System of Quality of Life Instruments for Chronic Diseases QLICD-CG Based on Classical Test Theory and Generalizability Theory.

Authors:  Chonghua Wan; Ying Chen; Li Gao; Qingqing Zhang; Wu Li; Peng Quan
Journal:  J Clin Gastroenterol       Date:  2022-02-01       Impact factor: 3.174

5.  Diet quality in cystic fibrosis - associations with patient reported outcome measures and enablers and barriers to eating a healthy diet: A protocol paper for a mixed methods study.

Authors:  Cian Greaney; Katie Bohan; Sarah Tecklenborg; Brian Casserly; James Green; Pepijn Van de Ven; Katie Robinson; Audrey Tierney
Journal:  HRB Open Res       Date:  2022-05-05
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.